

NEWS RELEASE



May 10, 2018

Presentations on NS-065/ NCNP-01 at 2018 New Directions in Biology and Disease of Skeletal Muscle Conference

Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters, Kyoto City; President, Shigenobu Maekawa) announced today that presentations on NS-065/ NCNP-01* which is being developed for the treatment of Duchenne Muscular Dystrophy (DMD) will be given at 2018 New Directions in Biology and Disease of Skeletal Muscle Conference to be held in New Orleans, LA in June 25 - 29, 2018.

Schedule	Wednesday, June 27, 2018 (Central Standard Time) (Detailed presentation schedule is not determined)
Speaker/ Subject	1. Paula Clemens, University of Pittsburgh A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys with Duchenne Muscular Dystrophy (DMD) 2. Hirofumi Komaki, National Center of Neurology and Psychiatry A Japanese Phase I/II study of NS-065/NCNP-01, Exon53 skipping drug, in patients with Duchenne muscular dystrophy -A dose-finding study-

* NS-065/NCNP-01 is a morpholino antisense oligonucleotide, which is expected to improve muscle function for DMD patients amenable to exon 53 skipping. It was co-discovered by Nippon Shinyaku and National Center of Neurology and Psychiatry (NCNP: Kodaira City, Tokyo; President, Hidehiro Mizusawa, Corporate director, Shin'ichi Takeda) and is a drug candidate which is expected to be an important option for DMD.